Meeting
2020 ASCO Virtual Scientific Program
Updated safety phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM.
Authors
Michael Lim
The Johns Hopkins Hospital, Baltimore, MD
Michael Lim , Xiaobu Ye , Anna F. Piotrowski , Arati Suvas Desai , Manmeet Singh Ahluwalia , Tobias Walbert , Joy D. Fisher , Serena Desideri , Louis B. Nabors , Patrick Y. Wen , Stuart A. Grossman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02658981
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2512)
DOI
10.1200/JCO.2020.38.15_suppl.2512
Abstract #
2512
Poster Bd #
3
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM.
First Author: Michael Lim
Poster
2020 ASCO Virtual Scientific Program
Escalation portion of phase II study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status.
First Author: Patrick Y. Wen
Poster
2019 ASCO Annual Meeting
Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma.
First Author: E. Antonio Chiocca
Poster
2018 ASCO Annual Meeting
Hypofractionnated stereotactic radiotherapy and anti-PDL1 durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial.
First Author: Damien Pouessel